Research
What Is Research?
Research is a study that is done to answer a question about a certain topic or disease. Scientists do research because they don’t know for sure what works best to help you. Participants in clinical trials can play a more active role in their own health care, gain access to new research treatments before they are widely available, and help others by contributing to medical research. Some other words that describe research are clinical trial, protocol, survey, or experiment. It is important to understand research is not the same as treatment.
Why Is Research Important?
Research has led to important discoveries that make our lives better. Research brings new drugs to treat stroke, cancer and diabetes. Research brings a better understanding about ultrasound, X-ray machines, and diagnostic tests. Research can improve medical procedures.
Points to consider while considering a research trial are, a research study may or may not help you personally. In the future, the results could help others who have a health problem. Most importantly taking part in research is voluntary.
Blue Sky Neurology is actively seeking participants for their current research studies. If you are interested and would like more information please contact any of the following investigators or our research coordinators:
- Ira Chang, MD (POINT trial)
- Chris Fanale, MD (IMS 3, SPS3)
- Robert Pratt, MD (ENGAGE)
- Jeffrey Wagner, MD
- Rod Spencer, MD
- Paula Fisk or Lenden Neeper at Colorado Neurological Institute
Phone: 303-806-7455 or www.thecni.org.
SPS3: Secondary Prevention of Small Subcortical Stroke - enrolling
The purpose of this trial is to gather information on the effectiveness of a combination of aspirin and clopidogrel medications to help prevent another stroke from happening in people who have suffered a stroke or a transient ischemic attack. At the same time, to see if lower blood pressure has effect to help prevent another stroke from happening in people who have suffered a stroke or a transient ischemic attack.
- Over 30 years of age
- A small stroke or TIA within 6 months
The study includes:
- Close Blood Pressure monitoring
- Study medication
- Doctor visits
Additional information on the SPS3 study
POINT:
Platelet-Oriented
Inhibition in New
TIA and minor ischemic stroke - enrolling
This is a study to determine whether clopidogrel (Plavix) taken
after a loading dose of 600 mg is effective in preventing major
ischemic vascular events (stroke, myocardial infarction or ischemic
vascular death) at 90 days when initiated within 12 hours of a TIA
or minor ischemic stroke onset. Patients will also be receiving
aspirin daily.
- 18 years old
- Had a TIA or small stroke
- NIHSS of 3 or less
- Must be treated within 12 hours from onset of TIA/stoke symptoms
Additional information on the POINT study
IMS III: A phase III, randomized, multi-center, open label trial to assess if intra-venous (IV) and intra-arterial (lA) approach to recanalization is superior to standard IV rt-PA (Activase®) alone when initiated within three hours of acute ischemic stroke onset - enrolling
This trial examines whether combined intravenous (IV) and intra-arterial (IA) treatment is superior to standard IV rt-PA alone when started within three hours of stroke onset.
- 18 – 82 years of age
- NIHSS of 8 of higher
- Must be able to initiated study medication within 3 hours from onset of stroke systems
ENGAGE AF-TIMI 48: Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 - enrollment complete
This study is comparing an experimental study medication to warfin with regards to clinical outcome of Stroke, adverse cardiovascular events and to major bleeding events related to warfarin in patients with atrial fibrillation and a recent stroke.
- Over the age of 21
- Documented atrial fibrillaton within the past 12 months
- Had a recent stroke
Additional information on the ENGAGE study
Closed to Enrollment Studies:
TRA 2°P – TIMI 50®
Although TIMI 50® is closed to enrollment, we are still following a
number of patients. This trial is researching the efficacy and
safety of a novel investigational anti-platelet agent in preventing
a recurrent stroke.